Pharmacopeia to Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
22 Oktober 2007 - 1:30PM
PR Newswire (US)
PRINCETON, N.J., Oct. 22 /PRNewswire-FirstCall/ -- Pharmacopeia
(NASDAQ: PCOP), an innovator in the discovery and development of
novel small molecule therapeutics, today announced that Dr. Leslie
J. Browne, President and Chief Executive Officer, will deliver a
corporate presentation at the Acumen BioFin Rodman & Renshaw
9th Annual Healthcare Conference. The conference will be held
November 5 - 7, 2007, at the New York Palace Hotel in New York
City. Dr. Browne's presentation will take place at 9:30 a.m. EST on
Monday, November 5th in the Kennedy II Room and will be immediately
followed by a Q&A session. The presentation will include an
overview of the company's drug development pipeline, including an
update on its clinical studies with PS433540 (DARA) and the
recently acquired PS178990 (SARM) program, recent corporate
accomplishments and upcoming milestones. A live webcast and 90-day
archive of the presentation can be accessed at
http://www.pharmacopeia.com/. ABOUT PHARMACOPEIA Pharmacopeia is a
clinical development stage biopharmaceutical company dedicated to
discovering and developing novel small molecule therapeutics to
address significant medical needs. The company has a broad
portfolio of clinical and preclinical candidates under development
internally or with partners including seven clinical compounds in
Phase 2 or Phase 1 development addressing hypertension, diabetic
nephropathy, muscle wasting, inflammation and respiratory disease.
The company is leveraging its fully integrated drug discovery
platform to sustain the growth of its development pipeline.
Pharmacopeia has established strategic alliances with major
pharmaceutical and biotechnology companies, including Bristol-Myers
Squibb, Cephalon, GlaxoSmithKline, Organon, Schering-Plough, and
Wyeth Pharmaceuticals. For more information please visit the
company's website at http://www.pharmacopeia.com/. This press
release, and oral statements made with respect to information
contained in this press release, constitute forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such forward-looking statements include those
which express plan, anticipation, intent, goal, contingency or
future development and/or otherwise are not statements of
historical fact. These statements are based upon management's
current expectations and are subject to risks and uncertainties,
known and unknown, which could cause actual results and
developments to differ materially from those expressed or implied
in such statements. These forward- looking statements include, but
are not limited to, statements about the successful implementation
of Pharmacopeia's strategic plans, Pharmacopeia's plans to develop
PS433540, a product candidate from its DARA program, Pharmacopeia's
Phase 2 and Phase 1 clinical studies with respect to PS433540,
including timing and expected outcomes of such studies,
Pharmacopeia's plans to develop PS178990, a product candidate from
its SARM program, Pharmacopeia's Phase 1 clinical studies with
respect to PS178990, including timing and expected outcomes of such
studies, Pharmacopeia's estimates of the market opportunities for
its product candidates, including PS178990 and PS433540,
Pharmacopeia's ability to successfully perform under its
collaborations with Bristol-Myers Squibb, Cephalon,
GlaxoSmithKline, Organon and Wyeth, Pharmacopeia's ability to build
its pipeline of novel drug candidates through its own
internally-funded drug discovery programs, third party
collaborations and in-licensing, Pharmacopeia's ability to raise
additional capital, Pharmacopeia's expectations concerning the
development priorities of its collaborators, their ability to
successfully develop compounds and its receipt of milestones and
royalties from the collaborations, Pharmacopeia's anticipated
operating results, financial condition, liquidity and capital
resources, Pharmacopeia's expectations concerning the legal
protections afforded by U.S. and international patent law,
Pharmacopeia's ability to pursue the development of new compounds
and other business matters without infringing the patent rights of
others, additional competition, and changes in economic conditions.
Further information about these and other relevant risks and
uncertainties may be found in Pharmacopeia's Reports on Form 8-K,
10-Q and 10-K filed with the U.S. Securities and Exchange
Commission. Pharmacopeia urges you to carefully review and consider
the disclosures found in its filings which are available in the SEC
EDGAR database at http://www.sec.gov/ and from Pharmacopeia at
http://www.pharmacopeia.com/. All forward-looking statements in
this press release and oral statements made with respect to
information contained in this press release are qualified entirely
by the cautionary statements included in this press release and
such filings. These risks and uncertainties could cause actual
results to differ materially from results expressed or implied by
such forward-looking statements. These forward-looking statements
speak only as of the date of this press release. Pharmacopeia
undertakes no obligation to (and expressly disclaims any such
obligation to) publicly update or revise the statements made herein
or the risk factors that may relate thereto whether as a result of
new information, future events, or otherwise. Contact: Amy P.
Sharpless Corporate Communications (609) 452-3643 DATASOURCE:
Pharmacopeia CONTACT: Amy P. Sharpless, Corporate Communications,
of Pharmacopeia, +1- 609-452-3643, Web site:
http://www.pharmacopeia.com/
Copyright